It is a phase I/IIa randomized, double-blind, placebo-controlled, single-centre, open-label continuation trial with expected results by March 2021 [127]; tamoxifen, that showed ability to enhance autophagy and decrease TDP-43 aggregation in a small randomized double-blind trial whose results revealed a slight effect on attenuating disease progression for six months [128]; or arimoclomol, a heat shock protein co-inducer with neuroprotective properties in SOD1 related ALS, which was tested in a randomized, double-blind, placebo-controlled trial and lacked an important therapeutic benefit [129]. Here, SOD1 is linked to amyotrophic lateral sclerosis.